News

Long-term daily use of Ingrezza (valbenazine) leads to a clinically meaningful easing of tardive dyskinesia (TD) — the repetitive and jerky movements caused by antipsychotics – and to high levels of patient satisfaction, data from a Phase 3 clinical trial of Neurocrine Biosciences’ treatment show. The results, “Effects of Long-Term Valbenazine on…

The Parkinson’s Foundation announced that it investing $6.2 million across 53 research grants, part of its commitment to advancing promising work into the disease. The grants will support Parkinson’s clinical trials and research centers. They also include career development and fellowships for scientists working in multiple aspects of related research. “Our goal at…

Thinning of the eye’s retina appears to be associated with Parkinson’s and, possibly, with disease severity, a study reports, suggesting that an eye scan might be used at some point to detect Parkinson’s in its earliest stages, before motor symptoms begin. The study, “Retinal thinning associates with nigral dopaminergic loss in…

A new online exercise training program for professionals working with Parkinson’s disease patients has been launched by the Brian Grant Foundation (BGF). This free program is geared toward physical therapists, personal trainers, and group fitness instructors to assist them in developing safe and effective training classes for those…

Tiny bleeds in the brain are associated with cognitive impairment in Parkinson’s disease and risk of Parkinson’s disease dementia (PDD), a Japanese study has found. The research, “The presence of cerebral microbleeds is associated with cognitive impairment in Parkinson’s disease,” was published in the Journal of…

Low-frequency subthalamic deep brain stimulation (STN-DBS), but not high-frequency STN-DBS, reduces freezing of gait in Parkinson’s patients while preserving their ability to simultaneously process motor and cognitive information, a recent study shows. The study, “Decreasing subthalamic deep brain stimulation frequency reverses cognitive interference during gait initiation in…

Low levels of a specific chaperone  protein might be implicated in the development of Parkinson’s disease and Lewy body dementia, according to new research. The protein may be a promising therapeutic target to treat Parkinson’s, with researchers pursuing this possibility in preclinical studies. The study, “…

Patients diagnosed with Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) were found to have a mortality rate more than three times higher than the general population, according to researchers in Sweden. The 10-year follow-up study, titled “Relative survival in patients with dementia with Lewy bodies…

Alpha-synuclein (aSyn), a protein linked to Parkinson’s disease and dementia with Lewy bodies (DLB), exerts its harmful effects by disrupting the normal function of protein production, a study has found. This sheds light on the involvement of the aSyn protein in Parkinson’s disease, confirming its potential as a…

Communication difficulties are caused by motor and/or cognitive impairment in people with Parkinson’s disease, a review study highlights. An interdisciplinary approach to assess changes in patients’ daily communications may help detect and monitor motor and cognitive symptoms in this population. The review, “Communication impairment in Parkinson’s disease: Impact…